Key result
Saxagliptin significantly decreased NPY3-36 concentrations during moderate intensity exercise compared to placebo, without affecting hemodynamics or catecholamine concentrations.
Why the study?
The secretions of NPY1–36 and NPY3–36 in response to sympathetic nervous system activation had not been studied due to a lack of analytical techniques to distinguish them.
Does saxagliptin alter neuropeptide Y and catecholamine kinetics or physiological responses during moderate and heavy intensity exercises in healthy male volunteers?
RCT (n=6)
Double-blind
Randomized crossover
No
Does saxagliptin alter neuropeptide Y and catecholamine kinetics or physiological responses during moderate and heavy intensity exercises in healthy male volunteers?
Answers are grounded in this paper and cite their sources.
DPP4 inhibition with saxagliptin alters the NPY1-36/NPY3-36 ratio but does not affect catecholamine release or hemodynamic responses during exercise in healthy volunteers.
Neuropeptide Y 1–36 (NPY1–36) is a vasoconstrictor peptide co-secreted with norepinephrine (NE) by nerve endings during sympathetic activation. NPY1–36 potentiates NE action post-synaptically through the stimulation of the Y1 receptor, whereas its metabolite NPY3–36 resulting from DPP4 action activates Y2 presynaptic receptors, inhibiting NE and acetylcholine secretion. The secretions of NPY1–36 and NPY3–36 in response to sympathetic nervous system activation have not been studied due to the lack of analytical techniques available to distinguish them. We determined in healthy volunteers NPY1–36, NPY3–36 and catecholamine kinetics and how these neurotransmitters modulate the physiological stress response during and after moderate- and heavy-intensity exercises. Six healthy males participated in this randomized, double-blind, saxagliptin vs placebo crossover study. The volunteers performed an orthostatic test, a 30-min exercise at moderate intensity and a 15-min exercise at heavy intensity each followed by 50 min of recovery in two separate sessions with saxagliptin or placebo. Oxygen consumption (V̇O2), ventilation and heart rate were continuously recorded. NE, epinephrine, NPY1–36 and NPY3–36 were quantified by tandem mass spectrometry. We found that exercise triggers NPY1–36 and NE secretion in an intensity-dependent manner and that NE returns faster to the baseline concentration than NPY1–36 after exercise. NPY3–36 rises during recovery parallel to the decline of NPY1–36. Saxagliptin reverses the NPY1–36/NPY3–36 ratio but does not affect hemodynamics, nor NPY1–36 and catecholamine concentrations. We found that NPY1–36 half-life is considerably shorter than previously established with immunoassays. NPY1–36 and NE secretions are finely regulated to prevent an excessive physiological Y1 stimulating response to submaximal exercise.
No takes yet. Share an insight, caveat, or question.
Eugster et al. (2022) conducted an RCT in Healthy volunteers (n=6). Saxagliptin vs. Placebo was evaluated on NPY3-36 concentration (AUC0-15min) during moderate intensity exercise (pM × min) (p=<0.001). Saxagliptin significantly decreased NPY3-36 concentrations during moderate intensity exercise compared to placebo, without affecting hemodynamics or catecholamine concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: